GAO Report: Increased Oversight Needed to Ensure Nongovernmental Hospitals Meet Eligibility Requirements
The 340B Drug Pricing Program (340B Program) and the Medicaid Drug Rebate Program require manufacturers to provide discounts on outpatient […]
GAO/OIG Reports
GAO Report: Oversight of the Intersection with the Medicaid Drug Rebate Program Needs Improvement
Under the 340B Drug Pricing Program (340B Program), administered by the U.S. Department of Health and Human Services’ (HHS) Health
GAO Report: Characteristics of Hospitals Participating and Not Participating in the 340B Program
The 340B Program allows certain types of hospitals to get discounted drugs. We compared characteristics of hospitals that did and
GAO Report: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement
To have their drugs covered under Medicaid, the “340B” program requires drug manufacturers to sell outpatient drugs to covered entities—certain
GAO Report: Update on Agency Efforts to Improve 340B Program Oversight
The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs at discounted prices to covered entities—eligible clinics, hospitals,
GAO Report: Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals
Certain providers, including hospitals that serve a disproportionate number of low-income patients, have access to discounted prices on outpatient drugs
GAO Report Summary
The Government Accountability Office (GAO) released a report on the Section 340B drug discount program, Manufacturer Discounts in the 340